A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer’s disease, researchers at Johns Hopkins University found
The drug, commonly used to treat epilepsy, calms hyperactivity in the brain of patients with amnestic mild cognitive impairment (aMCI), a clinically recognized condition in which memory impairment is greater than expected for a person’s age and which greatly increases risk for Alzheimer’s dementia, according to the study published this week in NeuroImage: Clinical.
The findings validate the Johns Hopkins team’s initial conclusions, published three years ago in the journal Neuron. They also closely match the results in animal studies performed by the team and scientists elsewhere. Next, neuroscientist Michela Gallagher, the lead investigator, hopes the therapy will be tested in a large-scale, longer-term clinical trial.
Hippocampal over-activity is well-documented in patients with aMCI and its occurrence predicts further cognitive decline and progression to Alzheimer’s dementia, Gallagher said.
“What we’ve shown is that very low doses of the atypical antiepileptic levetiracetam reduces this over-activity,” Gallagher said. “At the same time, it improves memory performance on a task that depends on the hippocampus.”
The team studied 84 subjects — 17 of them were normal healthy aged participants and the rest had the symptoms of pre-dementia memory loss defined as aMCI. Everyone was over 55 years old, with an average age of about 70.
The subjects were given varying doses of the drug and also a placebo in a double-blind randomized trial. Researchers found low doses both improved memory performance and normalized the over-activity detected by functional magnetic resonance imaging that measures brain activity during a memory task. The ideal dosing found in this clinical study matched earlier preclinical studies in animal models.
“What we want to discover now, is whether treatment over a longer time will prevent further cognitive decline and delay or stop progression to Alzheimer’s dementia,” Gallagher said.
The Latest on: Alzheimer’s Disease
via Google News
The Latest on: Alzheimer’s Disease
- 'It's going to touch all of us': What groups are doing to help people with dementiaon January 18, 2022 at 11:00 am
Hospice of the Valley, Banner Alzheimer's Institute and other Arizona nonprofits are serving patients with dementia. Here's how you can help.
- Biogen bet its Alzheimer’s drug could make billions. Here’s how it all fell apart.on January 18, 2022 at 9:31 am
In the first six months of its launch, Biogen's Alzheimer's drug Aduhelm has disappointed Wall Street and been rejected by European regulators.
- More than $1.7 Million in IDSA Foundation Grant Funds Attracts Diverse Minds to Alzheimer's Researchon January 18, 2022 at 8:30 am
The Infectious Diseases Society of America Foundation recently awarded more than $1.7 million in grant funds to advance ...
- Understanding memory loss in Alzheimer's diseaseon January 18, 2022 at 7:53 am
Members of the Synaptic Dysfunction and Disease group at the Institute of Biomedicine of Seville (IBiS), led by researchers Francisco Gómez Scholl and Amalia Martínez Mir, recently published the ...
- COVID-19 patients show more signs of brain damage than people with Alzheimer’s diseaseon January 17, 2022 at 1:09 pm
A new study reveals older patients contracting COVID have more signs of brain damage than people who develop the neurodegenerative disease.
- The Alzheimer's disease drug Aduhelm faces more troubleson January 14, 2022 at 2:00 pm
The drug Aduhelm (generic: aducanumab), when first introduced, was touted as a miracle drug for the treatment of Alzheimer’s disease. In fa | Drug Discovery And Development ...
- New Therapy May Delay Progression of Alzheimer’s Diseaseon January 13, 2022 at 6:37 pm
Alzheimer's Disease (AD) and other dementias cause a heavy economic and public healthcare burden worldwide. The number of people living with dementia continues to increase mainly due to population ...
- Coordinated Offensive on Alzheimer’s Diseaseon January 13, 2022 at 8:48 am
Alzheimer’s Disease (AD) is a feared diagnosis that afflicts many older individuals, particularly women and those with a genetic predisposition for the condition. AD is so frightening in large part ...
- A life-enhancing elixir? Olive oil linked to lower death risks from Alzheimer's disease, all causeson January 12, 2022 at 8:48 am
Researchers found those who consumed olive oil daily had lower risks of death from cancer, Alzheimer's disease, cardiovascular disease, other causes.
- Biogen’s stock tumbles after the U.S. proposes restricting access to its Alzheimer’s disease drugon January 12, 2022 at 6:44 am
Regulators have proposed limiting access to the class of Alzheimer's disease drugs that includes the company's therapy, Aduhelm.
via Bing News